Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free ANEB Stock Alerts

Anebulo Pharmaceuticals (ANEB) Stock Forecast & Price Target

Anebulo Pharmaceuticals logo
$0.46 0.00 (0.00%)
As of 11:33 AM Eastern
Compare

Anebulo Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Reduce
Based on 2 Analyst Ratings
Sell
1
Hold
1
Buy
0

Based on 2 Wall Street analysts who have issued ratings for Anebulo Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a hold rating for ANEB.

Consensus Price Target

$3.00
552.17% Upside
According to the 2 analysts' twelve-month price targets for Anebulo Pharmaceuticals, the average price target is $3.00. The highest price target for ANEB is $3.00, while the lowest price target for ANEB is $3.00. The average price target represents a forecasted upside of 552.17% from the current price of $0.46.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ANEB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Anebulo Pharmaceuticals and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ANEB Analyst Ratings Over Time

TypeCurrent Forecast
5/5/25 to 5/5/26		1 Month Ago
4/5/25 to 4/5/26		3 Months Ago
2/4/25 to 2/4/26		1 Year Ago
5/5/24 to 5/5/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$3.00$3.00$3.00$8.00
Forecasted Upside552.17% Upside300.00% Upside215.76% Upside607.96% Upside
Consensus RatingReduceReduceReduceBuy

ANEB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ANEB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Anebulo Pharmaceuticals Stock vs. The Competition

TypeAnebulo PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
1.50
2.30
2.52
Consensus RatingReduceHoldModerate Buy
Predicted Upside552.17% Upside911.32% Upside14.75% Upside
News Sentiment Rating
Neutral News

See Recent ANEB News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
10/8/2025
Weiss Ratings logo
Weiss Ratings
Not Rated
 Reiterated RatingSell (D-)
7/23/2025
Maxim Group logo
Maxim Group
1 of 5 stars
Michael Okunewitch
Michael Okunewitch
2 of 5 stars
DowngradeStrong-Buy ➝ Hold
11/19/2024
Benchmark Co. logo
Benchmark
4 of 5 stars
Robert Wasserman
3 of 5 stars
Reiterated RatingSpeculative Buy$8.00 ➝ $8.00+422.87%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 07:59 PM ET.


ANEB Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Anebulo Pharmaceuticals is $3.00, with a high forecast of $3.00 and a low forecast of $3.00.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anebulo Pharmaceuticals in the last twelve months. There is currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" ANEB shares.

According to analysts, Anebulo Pharmaceuticals's stock has a predicted upside of 552.17% based on their 12-month stock forecasts.

Analysts like Anebulo Pharmaceuticals less than other "medical" companies. The consensus rating for Anebulo Pharmaceuticals is Reduce while the average consensus rating for "medical" companies is Hold. Learn more on how ANEB compares to other companies.

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Anebulo Pharmaceuticals Recommendations


This page (NASDAQ:ANEB) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel